Medco Study Lets Januvia And Byetta Off The Hook For Pancreatitis
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharmaceutical benefits manager's review of almost 800,000 claims does not show higher risk for these two drugs, despite label warnings.
You may also be interested in...
Japan Market Approval On Track For All-Case Surveillance Drugs From Lilly, GSK, Otsuka
TOKYO - A string of drugs are on track for marketing approval in Japan, as the pharmaceutical subcommittee of the Pharmaceutical Affairs and Food Sanitation Council confirmed its consent for approval of 22 new drugs and additional indications
Raising The Bar For New Anticoagulants? Warfarin Genotype Study Finds Reduced Risk
Medco/Mayo study links more precise warfarin dosing through genotyping to a 30 percent reduction in hospitalization rates compared with patients not tested prior to starting therapy.
Byetta Needs More Studies To Determine Pancreatitis Risks, FDA Says
The previously undisclosed requirements are a setback to Amylin and Lilly, which jointly market the drug and plan a once-weekly version.